This clinical trial aims to investigate the efficacy of Calcipotriol ointment combined with 5-FU cream in Organ Transplant Recipients (OTRs) to determine if it can stimulate the immune cells against actinic keratoses precancerous skin lesions after transplantation and prevent cutaneous squamous cell carcinoma (SCC) in long-term.

Start Date01 Jan 2026

Sponsor / Collaborator

The General Hospital Corp.

[+1]

NCT04329221

/ WithdrawnPhase 2IIT

Calcipotriol Plus 5-Flourouracil Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

This clinical trial aims to investigate the efficacy of Calcipotriol ointment combined with 5-fluorouracil cream as an immunotherapy for actinic keratosis in Organ Transplant Recipients (OTRs) before transplantation and determine whether it can prevent cutaneous squamous cell carcinoma (SCC) in OTRs post-transplant.

Start Date01 Jan 2026

Sponsor / Collaborator

The General Hospital Corp.

[+1]

NCT07352566

/ Not yet recruitingPhase 4IIT

Utilization of a Cutaneous Therapy In Situ Microdevice

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Start Date01 Jan 2026

Sponsor / Collaborator

The University of California, San Francisco

100 Clinical Results associated with Calcipotriene

100 Translational Medicine associated with Calcipotriene

100 Patents (Medical) associated with Calcipotriene

1,789

Literatures (Medical) associated with Calcipotriene

01 Jan 2026·PHYTOTHERAPY RESEARCH

Sappanone A Exerted Strong Anti‐Inflammatory Effects in the Treatment of Atopic Dermatitis Through IL‐21R ‐Mediated JAK1 / STAT3 Pathway

Article

Author: Liu, Chenjie ; Wang, Cheng ; Li, Jiayi ; Ma, Pengcheng ; Li, Lingjun ; He, Jinkang ; Liu, Jun ; Li, Hongyang

ABSTRACT:

As a common dermatosis, atopic dermatitis (AD) is primarily driven by type 2 inflammation. Sappanone A (SA), derived from the traditional medicinal plant Caesalpinia sappan L., has demonstrated a broad range of anti‐inflammatory activities in various diseases. However, the pharmacological mechanisms underlying its efficacy remain unelucidated in AD. The objective of our research was to investigate the therapeutic efficacy and molecular mechanisms of SA in treating AD. In vitro, the anti‐inflammatory effects of SA were evaluated in IL‐4/IL‐13/TNF‐α stimulated HaCaT cells. In vivo, mice were treated with SA following the induction of AD‐like symptoms with MC903 and assessed for inflammatory parameters. Furthermore, transcriptomics and network pharmacology were utilized to elucidate the therapeutic mechanisms of SA in AD. SA significantly suppressed the generation of type 2 inflammatory cytokines in HaCaT cells stimulated by IL‐4/IL‐13/TNF‐α and alleviated MC903‐induced AD‐like symptoms in C57BL/6J mice. The integration of transcriptomics and network pharmacology displayed that SA regulated the type 2 inflammatory response in AD through the IL‐21R‐mediated JAK1/STAT3 signaling pathway. SA exerted a strong anti‐inflammatory role in treating AD by inhibiting the activation of the JAK1/STAT3 signaling pathway mediated by IL‐21R. This research not only supports the potential of SA as a novel agent for treating AD, but also offers methods for studying compounds derived from natural herbs in AD therapy.

02 Dec 2025·INTERNATIONAL JOURNAL OF NEUROSCIENCE

Clinical efficacy observation of calcipotriol combined with AYJ sodium alginate repair dressing in the treatment of psoriasis vulgaris and its effect on patients’ neurological function

Article

Author: Xiao, Min ; Lin, Min ; Lu, Yonghong ; Wang, Yan ; Chen, Zhonghua

OBJECTIVE:

To observe the clinical efficacy of calcipotriol combined with AYJ(An Yi Jia) sodium alginate repair dressing in the treatment of psoriasis vulgaris (PV) and its effect on patients' neurological function.

METHODS:

A retrospective analysis was conducted on the clinical data of 103 patients with PV admitted to our hospital from January 2022 to January 2024. All patients met the inclusion and exclusion criteria. According to the treatment interventions received by the patients, they were divided into control group (n = 51, receiving calcipotriol monotherapy) and observation group (n = 52, receiving calcipotriol combined with AYJ sodium alginate repair dressing). The clinical treatment effects, severity of the disease (PSSI score), levels of T lymphocyte subsets (CD4+, CD8+), serum nerve growth factor (NGF), inflammatory factors [interferon-gamma (IFN-γ), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-α)], and adverse reactions were compared between the two groups.

RESULTS:

① Clinical treatment effects: The total effective rate in the observation group was higher than that in the control group (p < 0.05). ② Severity of the disease: The PASI scores of both groups gradually decreased with prolonged treatment time, and the observation group showed a greater magnitude of change (p < 0.05). ③ T lymphocyte subset cells and serum nerve growth factor: The levels of CD4+ were increased after treatment in both groups, while CD8+ and NGF levels were decreased compared to before treatment, with a greater magnitude of change in the observation group (p < 0.05). ④ Inflammatory factors: The levels of IFN-γ, IL-8, and TNF-α were decreased after treatment in both groups, with a greater magnitude of change in the observation group (p < 0.05). ⑤ Adverse reactions: There was no significant difference in the incidence of adverse reactions between the two groups (p > 0.05).

CONCLUSION:

Calcipotriol combined with AYJ sodium alginate repair dressing has ideal therapeutic effects in the treatment of PV. Compared with calcipotriol alone, the combined application of AYJ sodium alginate repair dressing can further improve patient efficacy, improve immune and neurological function, alleviate patient inflammatory responses, and does not increase the risk of adverse reactions in patients.

01 Dec 2025·MOLECULAR DIVERSITY

Molecular insights of vitamin D receptor SNPs and vitamin D analogs: a novel therapeutic avenue for vitiligo

Article

Author: Kuriakose, Beena Briget ; Muthusamy, Karthikeyan ; Jeyaraman, Sabareeswari ; Alhazmi, Amani Hamad ; Sundaravel, Sakthi Sasikala ; Jagannathan, Sushma Shruthi

Vitamin D receptor (VDR) agonists play a pivotal role in modulating immune responses and promoting melanocyte survival, making them potential candidates for vitiligo treatment. The VDR gene is integral to mediating the effects of vitamin D in the immune system, and disruptions in its structure due to missense mutations may significantly contribute to the pathogenesis of vitiligo. Missense single-nucleotide polymorphisms (SNPs) can alter the amino acid sequence of the VDR protein, potentially affecting its ligand-binding affinity and downstream signaling. Investigating these missense SNPs provides critical insights into the genetic underpinnings of vitiligo and may help identify biomarkers for early detection and precision-targeted therapies. This study explored the therapeutic potential of vitamin D analogs in vitiligo management, with a particular focus on their binding interactions and molecular efficacy. Using molecular docking and virtual screening, 24 vitamin D analogs were evaluated. Calcipotriol exhibited the highest binding affinity (-11.4 kcal/mol) and unique interactions with key residues in the VDR ligand-binding domain. Additionally, an analysis of structural variations stemming from missense mutations in the VDR gene highlighted potential impacts on receptor-ligand interactions, further emphasizing the importance of genetic factors in treatment response. These findings underscore the potential of calcipotriol to promote melanogenesis and modulate pigmentation in vitiligo. A comparative analysis identified structural variations influencing the efficacy of other analogs, such as calcitriol and tacalcitol. Although the in silico methods provided valuable insights, the study acknowledges the limitations of excluding dynamic cellular environments and emphasizes the need for experimental validation. Overall, this study enhances our understanding of VDR-targeted therapies, and calcipotriol is a promising candidate for further development in the management of vitiligo.

News (Medical) associated with Calcipotriene

06 Jan 2026

·mc2therapeutics.com

MC2 Therapeutics Announces Dosing of the first patient in the Wynzora® Phase III Clinical Trial in China

Copenhagen, January 6, 2026 – MC2 Therapeutics, a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and dry and itchy skin and Hangzhou Zhongmei Huadong Pharmaceutical Co (“Huadong”), a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), announces that the first subject in the Huadong sponsored phase III clinical study evaluating the efficacy and safety of Wynzora® Cream for the treatment of plaque psoriasis in Chinese patients has successfully been enrolled and dosed. In July 2025, the Phase III clinical trial application filed by Zhongmei Huadong, was approved by the National Medical Products Administration (NMPA) of China. The completion of the first patient enrollment in the phase III clinical trial of MC2-01 Cream marks a significant milestone in the product’s development process in China and it will further enhance Huadong’s competitiveness in the fields of autoimmune diseases and topical dermatological formulations. Huadong will fully advance the clinical development and registration of the product in China, striving to provide more treatment options for Chinese psoriasis patients. About Wynzora® Cream Wynzora® Cream is a cream-based fixed dose combination of calcipotriol and betamethasone dipropionate for topical treatment for plaque psoriasis, including scalp psoriasis, in adults. Its dual mode of action is targeting the hallmark cytokines IL-23 and IL-17A/F immune axis and TNF-α expression in a single product. Wynzora® Cream is uniquely enabled by MC2’s formulation and drug delivery system PAD Technology™, allowing an effective convenient-to-use aqueous formulation. Wynzora® Cream was approved in the US 2020, in the European countries 2021, in Australia November 2024 and in Canada November 2025. About MC2 Therapeutics A/S MC2 Therapeutics is a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and dry and itchy skin through innovative and effective therapies. The company is dedicated to improving the lives of people with plaque psoriasis and inflamed dry and itchy skin through innovative and effective therapies and support. Wynzora® Cream is partnered with leading pharmaceutical companies specializing in dermatology covering more than 40 countries in four continents. The company is based in Hørsholm, Denmark and in Guildford, United Kingdom. For additional information on MC2 Therapeutics, please visit https://www.mc2therapeutics.com Contact: Trine Ahlgreen, +45 3150 5036, info@mc2therapeutics.com About Huadong Medicine Huadong Medicine Co., Ltd. (SZ.000963) is a leading Chinese pharmaceutical company based in Hangzhou, China. Founded in 1993, Huadong Medicine has fully integrated R&D, manufacturing, distribution, sales, and marketing capabilities. Huadong Medicine’s product portfolio and pipeline are specialized in oncology, immunology, nephrology, and diabetes. The company has 14,000 employees and one of the most extensive commercial coverage and marketing capabilities in China. ‘Patient Centered, Science Driven’ is Huadong Medicine’s value. For additional information, please visit www.eastchinapharm.com. Contacts: Bo Chen, +86 571 8990 3290, ir@eastchinapharm.com BACK

Phase 3Drug Approval

04 Jan 2026

·mc2therapeutics.com

MC2 Therapeutics Announces License and Commercialization Agreement for Wynzora® Cream in Australia

Copenhagen, January 5, 2026 – MC2 Therapeutics, a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and dry and itchy skin announces today an agreement granting exclusive rights to Actor Pharmaceuticals Pty Ltd, to commercialize MC2’s Wynzora® Cream for the treatment of plaque psoriasis for adults in Australia. Wynzora® Cream was approved by The Australian Government Department of Health and Aged Care (Therapeutic Goods Administration) November 11, 2024, for topical treatment of mild to moderate plaque psoriasis on the body in adults and for treatment of scalp psoriasis. “Actor Pharmaceuticals is an Australian pharmaceutical company marketing innovative and branded pharmaceutical products. With Actor’s expertise, ambition and strategy to develop a meaningful dermatology portfolio, Actor is an excellent partner for MC2 to bring Wynzora® to Australian patients” said Trine Ahlgreen, Chief Executive Officer of MC2 Therapeutics. “This partnership supports our mission to make Wynzora® available to as many patients suffering from plaque psoriasis as possible.” “We look forward to working with MC2 to make Wynzora® Cream available to Australians who suffer from plaque psoriasis,” said Mark Jaggers, Chief Commercial Officer of Actor Pharmaceuticals. “Wynzora® Cream’s unique formulation and clinical profile will offer patients a new treatment option designed for effect and satisfaction in daily routines. Feedback from other countries where Wynzora® has been launched gives us confidence that Wynzora will also be welcomed by Australian patients.” About Wynzora® Cream Wynzora® Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment for plaque psoriasis, including scalp psoriasis, in adults. Its dual mode of action is targeting the hallmark cytokines IL-23 and IL-17A/F immune axis and TNF-α expression in a single product. Wynzora® Cream is uniquely enabled by MC2’s formulation and drug delivery system PAD Technology™, allowing an effective convenient-to-use aqueous formulation. Wynzora® Cream was approved in the US by the FDA on July 20th, 2020, and in the first country in Europe on July 9th, 2021. About MC2 Therapeutics A/S MC2 Therapeutics is a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and dry and itchy skin through innovative and effective therapies. The company is dedicated to improving the lives of people with plaque psoriasis and inflamed dry and itchy skin through innovative and effective therapies and support. Wynzora® Cream is partnered with leading pharmaceutical companies specializing in dermatology covering more than 40 countries in four continents. The company is based in Hørsholm, Denmark and in Guildford, United Kingdom. For additional information on MC2 Therapeutics, please visit https://www.mc2therapeutics.com Contact: Trine Ahlgreen, +45 3150 5036, info@mc2therapeutics.com About Actor Pharmaceuticals PTY, LTD. Actor Pharmaceuticals., headquartered in Sydney, Australia, is a specialty pharmaceutical company focused on providing best-in-class pharmaceuticals, biosimilar medicines and over-the-counter products to healthcare professionals and consumers on the Australian and New Zealand market. For more information, visit www.actorpharma.com.au/ BACK

Drug ApprovalLicense out/in

07 Nov 2025

·www.prnewswire.com

ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut

SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced that the Company will present one of its autoimmune and inflammation pipeline assets, CS2015 (OX40L/TSLP bispecific antibody), in the format of an ePoster plus an on-site oral presentation at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). ACAAI is one of the most influential academic conferences in the fields of allergies, asthma, and immunology, attracting experts and scholars around the world to discuss the latest scientific advancements. This marks the first presentation of CS2015 at an international academic conference. The full content of the abstract and eposter is now officially available on the ACAAI website. Key highlights of the presentation: CS2015 features an asymmetric molecular design that simultaneously targets OX40L and TSLP, two clinically validated critical regulators of type 2 inflammation. The molecule incorporates an engineered Fc region with reduced binding affinity for FcγR, which extends its in vivo half-life and optimizes its pharmacokinetic (PK) profile to support long-term dosing intervals. CS2015 also exhibits excellent molecular stability, facilitating the development of high-concentration subcutaneous formulations. Its strong developability profile further supports high-yield and scalable manufacturing. 1. Dual Blockade: CS2015 lead molecule demonstrated potent inhibition of OX40L/OX40 and TSLP/TSLPR downstream signaling: CS2015 potently interrupted the engagement of hOX40L on hOX40 reporter cells and hTSLP on hTSLPR/IL-7Rα reporter cells, respectively; The blocking activities of CS2015 were comparable to those of benchmark (parental) antibodies, with single or sub nanomolar IC50s. 2. Robust Inhibition of Inflammatory Responses: CS2015 lead molecule inhibited the release of inflammatory cytokines from primary CD4+ T cells stimulated by TSLP/OX40L and suppressed TSLP-induced release of TARC (CCL17) in human monocytes and peripheral blood mononuclear cells (PBMC). 3. Early Signs of Efficacy: CS2015 demonstrated potent disease control activities in Atopic Dermatitis (AD) model with OX40 and TSLP humanized mice. In MC903-induced AD models, CS2015 lead molecule: Rapidly reduced skin lesion severity including ear and epidermal thickening; Decreased immune cells, especially mast cells infiltration; Reduced itch events. 4. Durability Advantage: CS2015 demonstrated superb PK profiles in Non-Human Primate (NHP), supporting long-term dosing intervals: CS2015 lead molecule K19LS exhibited a mean half-life of 21 days (504.6 hours, Subcutaneous [SC]) and 25.7 days (617.6 hours, Intravenous [IV]); K19LS had a clearance rate of 2.4 (SC) and 2.7 (IV) ml/day/kg, and was well-absorbed, with outstanding bioavailability. 5. Outstanding drug-like properties: Beyond the data shown in the poster, CS2015 further demonstrated: Outstanding accelerated stability under high-temperature stress (40°C); Low viscosity (scored at only 3.7 for a 100 mg/ml solution), promising for subcutaneous injection at high-concentration; Potent efficacy in the intranasal OVA/TSLP-induced asthma model by decreasing the secretion of IL-4, CCL17, IgE, etc., and alleviating pulmonary pathological changes. CStone will further advance the development of CS2015 to treat Th2 cell-mediated inflammation diseases, including AD, asthma, hidradenitis suppurativa (HS), chronic obstructive pulmonary disease (COPD), Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), etc. The presentation schedule is as follows: Title: CS2015 a TSLP/OX40L Bispecific Antibody as a Potential Novel Therapeutic Agent for Type 2 Inflammation Diseases Presentation Type: ePoster display & 15-min on-site oral presentation (ePoster ID: R377) Abstract ID: 8079 Date & Time: Friday, November 7, 3:05 PM ET Location: ePoster Area of the West Exhibit Hall, Monitor 22 *The abstract and ePoster have been officially available on ACAAI website: . About CStone CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications covering 9 indications. The company's pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit: . Forward-looking statements The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments. Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes. SOURCE CStone Pharmaceuticals 21% more press release views with Request a Demo

AACRClinical Result

100 Deals associated with Calcipotriene

External Link

KEGG	Wiki	ATC	Drug Bank
D01125	Calcipotriene	D05AX02	DB02300

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Psoriasis	China	LEO Pharmaceutical Products OOO	07 Aug 2001
Psoriasis vulgaris	Japan	Leo Pharma, Inc.	18 Jan 2000
Plaque psoriasis	United States	LEO Pharma A/S	29 Dec 1993

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Psoriasis of scalp	Phase 3	Canada	Leo Pharma, Inc.	01 Nov 2004
Psoriasis of scalp	Phase 3	Denmark	Leo Pharma, Inc.	01 Nov 2004
Psoriasis of scalp	Phase 3	France	Leo Pharma, Inc.	01 Nov 2004
Psoriasis of scalp	Phase 3	Norway	Leo Pharma, Inc.	01 Nov 2004
Psoriasis of scalp	Phase 3	Portugal	Leo Pharma, Inc.	01 Nov 2004
Psoriasis of scalp	Phase 3	Spain	Leo Pharma, Inc.	01 Nov 2004
Psoriasis of scalp	Phase 3	Sweden	Leo Pharma, Inc.	01 Nov 2004
Psoriasis of scalp	Phase 3	United Kingdom	Leo Pharma, Inc.	01 Nov 2004
Arthritis, Psoriatic	Phase 2	France	Leo Pharma, Inc.	01 Apr 2015
Dermatitis, Atopic	Phase 2	Canada	Leo Pharma, Inc.	01 Oct 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EADV2022	Phase 3	Psoriasis of scalp	-	CAL/BDP cream	xjipyckkyy(bwvfuhmntb) = cybtlavbei qdakvsdjrn (sfsbvybokx ) View more	-	07 Sep 2022
				Vehicle cream	xjipyckkyy(bwvfuhmntb) = wnvxlfqcze qdakvsdjrn (sfsbvybokx ) View more
EADV2022	Phase 3	Plaque psoriasis	-	Calcipotriene (CAL) and betamethasone dipropionate (BDP) cream	lmldhcvgni(cvvjylilzv) = higdwyskib xweimfihmg (ehrolixcjz ) View more	-	07 Sep 2022
				Vehicle	lmldhcvgni(cvvjylilzv) = tflmvftybo xweimfihmg (ehrolixcjz ) View more
phase 3 (EADV2022)	Phase 3	Plaque psoriasis	796	Calcipotriene and betamethasone dipropionate cream	esatxlippu(xeqdmmrqai) = qxpfznbudu hxrwwweezb (rgoxcddfnf ) View more	Positive	07 Sep 2022
				Calcipotriene and betamethasone dipropionate gel	esatxlippu(xeqdmmrqai) = nsjtpgutrt hxrwwweezb (rgoxcddfnf ) View more
Pubmed Manual	Not Applicable	Psoriasis vulgaris	166	Calcipotriene+LEO90100	xglyzsvkit(ktdkbbglla) = qsfxuxhqir rpudwecxlq (qfmcdcffvs, 3.0) View more	Positive	18 Jul 2022
NCT00704262 (CTgov)	Phase 2	Psoriasis vulgaris	33	LEO 80190+Calcipotriol+hydrocortisone	vcoerfxprw = dyxlvghfcy xdbieawixq (umwaqulocn, pvdjyegomi - dtwtfuybnq) View more	-	20 Oct 2020
NCT01694433 (CTgov)	Phase 2/3	Acne Vulgaris	66	Calcipotriene (Calcipotriene Cream)	nvqfugnddq(bnwkwiqxgr) = gbcmdtkeus zufekqxkcq (ulrleyphnf, virboiodvz - aaatjburpf) View more	-	07 May 2019
				Placebo (Placebo)	nvqfugnddq(bnwkwiqxgr) = kouoltmjht zufekqxkcq (ulrleyphnf, udxajwmiph - agfiooionk) View more
NCT02411643 (CTgov)	Early Phase 1	Scleroderma, Localized	2	topical calcipotriene 0.005% ointment	hgihokvhrl(zbzkfbqrdg) = aqysbnvzlq oyzdcqbnji (oltwscxoqd, qkfxdpwcuf - xdcubctwxd) View more	-	13 Sep 2018
NCT00656019 (CTgov)	Phase 2	Breast Cancer	63	Vitamin D (Normal Vitamin D Levels)	yltquvocfg = riocqzbudq hbekcovrep (ucmnxggois, ctkctkrvjg - hximgkbmfx)	-	02 Dec 2017
				Vitamin D (Low-normal Vitamin D Levels)	yltquvocfg = flzmuyzkdv hbekcovrep (ucmnxggois, olfqqpmmyu - eyqwqgukgf)
NCT02132936 (PSO-ABLE, Pubmed \| Am J Clin Dermatol)	Phase 3	Psoriasis	504	Cal/BD foam	kwnfkzxado(cbegryqogl) = kvabwlxcme vvddtbkdzy (dgqpxxeyro ) View more	-	01 Jun 2017
				Cal/BD gel	kwnfkzxado(cbegryqogl) = wrjmakftwa vvddtbkdzy (dgqpxxeyro ) View more
NCT01745133 (CTgov)	Phase 4	Plaque psoriasis	63	vehicle foam	jhhmdhufmb(zqbqgzfnmz) = dgzlennkac tryufeooly (ydfbojovpq, qgndxupock - flfundidoz) View more	-	17 Nov 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis